Impact of glucose levels on advanced glycation end products in hemodialysis.
The current obesity epidemic throughout the western world has resulted in a considerable increase in the condition Type II diabetes mellitus. Recently, the World Health Organization has predicted that the global prevalence of Type II will increase from 175 million patients in 2003 to over 350 million by 2030. One of the major consequences of this disorder is renal failure, which presents itself as chronic kidney disease, and can progress to end-stage renal disease. Once diagnosed, patients are generally treated using dialysis due to a shortage of kidney donors. The fundamental process of dialysis still requires improvement because the survival rate of these patients is relatively poor. This has resulted in considerable research into improvements in hemodialysis membranes, and the challenge to find more suitable marker(s) in assessing the efficacy of the dialysis process. A class of compounds highlighted as a possible accumulative toxin is advanced glycation end products or AGEs. This is an article regarding the impact of hemodialysis and hemodiafiltration on glucose and AGE levels within the body and the consequences of a chronic hyperglycemic condition. It also highlights the negative aspects of using dextrose in conventional dialysis solutions (an area that has already been identified by peritoneal dialysis clinicians as problematic). The review concludes by suggesting several possible topics of future research.
Godfrey
Amy Ruth
AR
Institute of Mass Spectrometry, School of Medicine, Swansea University, Swansea, UK. 334215@swansea.ac.uk
D001786:Blood Glucose / Q000378:metabolism*; D002908:Chronic Disease; D048909:Diabetes Complications / Q000097:blood* / Q000401:mortality / Q000628:therapy; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000401:mortality / Q000628:therapy; D017127:Glycation End Products, Advanced / Q000097:blood*; D017583:Hemodiafiltration / Q000009:adverse effects; D006801:Humans; D006943:Hyperglycemia / Q000097:blood / Q000209:etiology / Q000401:mortality; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000209:etiology / Q000401:mortality / Q000628:therapy
D001786:Blood Glucose; D017127:Glycation End Products, Advanced